Jubilant out-licenses BET inhibitors to Checkpoint
Executive Summary
In its first out-licensing deal, Jubilant Biosys Ltd. granted Checkpoint Therapeutics Inc. exclusive global rights to patents covering BRD4 inhibitor compounds for cancer; BRD4 is a member of the BET (Bromodomain and Extra Terminal) domain.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice